408 results on '"Stewart, Tyler"'
Search Results
52. Impact of chemotherapy on anxiety, depression, and suicidality amongst testicular cancer survivors.
53. Comparison of urine cell-free DNA with blood-based screening for detection of bladder cancer.
54. Exploration of immunosuppressive features of the tumor microenvironment within hepatic and non-hepatic tumors of urothelial origin.
55. The effects of Mo2C additions on the microstructure and sliding wear of TiC0.3N0.7–Ni3Al cermets
56. The Current and Future Promises of Combination Radiation and Immunotherapy for Genitourinary Cancers
57. Association Between Primary Care Use Prior to Cancer Diagnosis and Subsequent Cancer Mortality in the Veterans Affairs Health System
58. The sliding wear of TiC and Ti(C,N) cermets prepared with a stoichiometric Ni3Al binder
59. Atezolizumab in understudied populations with bladder cancer
60. A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy.
61. Landscape analysis of urothelial carcinoma (UC) by telomerase reverse transcriptase (TERT) alterations.
62. Increasing primary care utilization prior to cancer diagnosis in association with cancer mortality.
63. An evaluation of trends in the representation of patients by age, sex, and diverse race/ethnic groups in bladder and kidney cancer clinical trials
64. Capítulo 156 - Cáncer de tiroides y nódulos tiroideos
65. Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC).
66. Impact of selection bias on outcomes in veterans with muscle-invasive bladder cancer receiving bladder preserving trimodality therapy.
67. Association between health-care system and prostate cancer mortality for African American men with localized and metastatic prostate cancer.
68. Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer
69. Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance
70. Treatment Discontinuation in Patients With Muscle-Invasive Bladder Cancer Undergoing Chemoradiation
71. Association of Health-Care System and Survival in African American and Non-Hispanic White Patients With Bladder Cancer
72. Analysis of CDK12 alterations in a pan‐cancer database
73. Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer
74. Characteristics of FDA drug recalls: A 30-month analysis
75. The Current and Future Promises of Combination Radiation and Immunotherapy for Genitourinary Cancers.
76. Association of prior local therapy and outcomes with programmed‐death ligand‐1 inhibitors in advanced urothelial cancer
77. Patterns of Failure After Definitive Treatment of T4a Larynx Cancer
78. Evaluating the clinical trends and benefits of low‐dose computed tomography in lung cancer patients
79. Chapter 156 - Thyroid Cancer and Thyroid Nodules
80. N-Acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy
81. Active surveillance for intermediate‐risk prostate cancer in African American and non‐Hispanic White men
82. Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes
83. What does it mean to 'stand on guard for thee'? Detuning the Canadian national anthem
84. Response and outcomes to immune checkpoint inhibitors (ICI) in advanced urothelial cancer (aUC) based on prior intravesical BCG.
85. Patterns of failure after definitive treatment for T4a larynx cancer in the Veterans Affairs Health System.
86. Association of increased intensity of prostate-specific antigen screening in younger African American men with improved prostate cancer outcomes.
87. Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).
88. Patterns of Failure After Definitive Treatment of T4a Larynx Cancer.
89. Association of Health-Care System With Prostate Cancer-Specific Mortality in African American and Non-Hispanic White Men
90. Association of race and health care system with disease stage and survival in veterans with larynx cancer
91. “Having Walked Alongside You”: A Conversational Exchange on Territory and Sound in Motion
92. Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).
93. Analysis of germline alterations and testing patterns in Hispanic men with prostate cancer.
94. The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone-sensitive prostate cancer.
95. Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.
96. Impact of equal access healthcare on race disparities in bladder cancer.
97. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
98. Prognostic Utility of Pretreatment Neutrophil-Lymphocyte Ratio in Advanced Larynx Cancer
99. Quantitative assessment of successive carbohydrate additions to the clusteredO-glycosylation sites of IgA1 by glycosyltransferases
100. Melt-Infiltration Processing of Titanium Carbide-Stainless Steel Cermets
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.